Common Contracts

SECOND AMENDED AND RESTATED VOTING AGREEMENT

Voting Agreement • February 11th, 2022 • Armata Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware

• Contract Type
  Voting Agreement
• Filed
  February 11th, 2022
• Company
  Armata Pharmaceuticals, Inc.
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  Delaware

This SECOND AMENDED AND RESTATED VOTING AGREEMENT (this “Agreement”) is made and entered into as of February 9, 2022 (the “Effective Date”), by and among Armata Pharmaceuticals Inc., a Washington corporation (the “Company”), Innoviva, Inc., a Delaware corporation (“Innoviva”), and Innoviva Strategic Opportunities LLC, a Delaware limited liability company and wholly-owned subsidiary of Innoviva (“Strategic Opportunities” and together with Innoviva, the “Stockholders”).

AMENDED AND RESTATED VOTING AGREEMENT

Voting Agreement • October 29th, 2021 • Armata Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware

• Contract Type
  Voting Agreement
• Filed
  October 29th, 2021
• Company
  Armata Pharmaceuticals, Inc.
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  Delaware

This AMENDED AND RESTATED VOTING AGREEMENT (this “Agreement”) is made and entered into as of October 28, 2021 (the “Effective Date”), by and between Armata Pharmaceuticals Inc., a Washington corporation (the “Company”), Innoviva, Inc., a Delaware corporation (“Innoviva”) and Innoviva Strategic Opportunities LLC (a Delaware limited liability company and wholly-owned subsidiary of Innoviva, “Strategic Opportunities” and together with Innoviva, the “Stockholders”).

VOTING AGREEMENT

Voting Agreement • January 27th, 2021 • Armata Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware

• Contract Type
  Voting Agreement
• Filed
  January 27th, 2021
• Company
  Armata Pharmaceuticals, Inc.
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  Delaware

This VOTING AGREEMENT (this “Agreement”) is made and entered into as of January 26, 2021 (the “Effective Date”), by and between Armata Pharmaceuticals Inc., a Washington corporation (the “Company”), Innoviva, Inc., a Delaware corporation (“Innoviva”) and Innoviva Strategic Opportunities LLC (a Delaware limited liability company and wholly-owned subsidiary of Innoviva, “Strategic Opportunities” and together with Innoviva, the “Stockholders”).